Bio


Dr. Appelbaum’s research focuses on the biology and treatment of leukemias, lymphomas and other blood cancers. He was the lead author of the first paper to describe the successful use of autologous bone marrow transplantation, a therapy now used in more than 30,000 patients annually. He was also a key contributor to the discovery and development of gemtuzumab ozogamicin, known commercially as Mylotarg, the first monoclonal antibody approved by the Food and Drug Administration to treat acute myeloid leukemia.

Institution


Seattle Cancer Care Alliance President
Fred Hutch Executive Vice President and Deputy Director

Links